[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jemincare\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":481},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,41,65,85,105,130,154,178,199,220,246,266,288,312,333,355,375,394,414,439,460],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100636419","phase-1-drug-drug-interactions-of-jmkx003142-in-healthy-participants-100636419",false,"NCT07565441","Drug-Drug Interactions of JMKX003142 in Healthy Participants","A Single-center, Non-randomized, Open-label, Self-controlled, Phase I Clinical Study to Evaluate Drug-Drug Interactions (DDI) of JMKX003142 Tablets in Chinese Healthy Participants.","Inclusion Criteria:\n\n1. Participants are able to return to the study center for follow-up as required by the protocol and are willing to comply with study policies, procedures, and restrictions; capable of effective communication with the investigator and completing study-related materials; able to understand the contents of the Informed Consent Form (ICF) and sign the written ICF prior to any study procedures.\n2. Healthy Chinese male or female subjects, as determined by medical history and physical examination. At the time of signing the Informed Consent Form (ICF), aged 18-45 years (inclusive) ; body weight ≥ 50 kg for males or ≥ 45 kg for females; and Body Mass Index (BMI) within the range of 19.0-26.0 kg\u002Fm² (inclusive).\n3. Participants were considered healthy by the Investigator based on medical history, baseline physical examination, clinical laboratory assessments, and 12-lead ECG, with all results judged as normal or not clinically significant.\n4. Participants of childbearing potential who agree to use effective contraception and have no plans for conception, cryopreservation, or donation of gametes from ICF signature through 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to JMKX003142 (active ingredient or excipients), or a history of hypersensitivity to more than two drugs, foods, or other substances.\n2. History or presence of clinically significant diseases in any of the following systems (including but not limited to): cardiovascular, respiratory, gastrointestinal, hematologic, genitourinary, endocrine\u002Fmetabolic, nervous, psychiatric, musculoskeletal, dermatologic, lymphatic, immune, or sensory organs; or current active local or systemic infection.\n3. Any condition increasing the risk of bleeding, such as acute gastritis, active ulcer with hemorrhage, clinically significant thrombocytopenia or anemia, active pathological bleeding, or a history of intracranial hemorrhage.\n4. Vital signs meet any of the following criteria at screening: systolic blood pressure ≥ 140 mmHg or \\\u003C 90 mmHg; diastolic blood pressure ≥ 90 mmHg or \\\u003C 50 mmHg; pulse rate \\> 100 bpm or \\\u003C 50 bpm; or tympanic temperature ≥ 37.5°C or \\\u003C 35°C.\n5. Subjects with a history of QTc interval prolongation or a family history of Long QT Syndrome; or those with clinically significant abnormal ECG findings as determined by the Investigator during screening; or a QTcF ≥ 450 ms; or a QRS interval \\> 120 ms.\n6. Positive for Hepatitis B surface antigen (HBsAg), Hepatitis C virus (HCV) antibody, Human Immunodeficiency Virus (HIV) antibody, or syphilis serology.\n7. Treatment with therapeutic biological products within 3 months (or 5 half-lives, whichever is longer) prior to dosing, or other prescription\u002Fnon-prescription medications (including vaccines, Traditional Chinese Medicine \\[TCM\\], dietary supplements, and health products) within 1 month (or 5 half-lives, whichever is longer).\n8. Use of any investigational drug within 3 months prior to screening, or current participation in another clinical trial.\n9. Major surgery (e.g., requiring general or epidural anesthesia) within 3 months prior to screening, or planned surgical intervention during the study.\n10. History of hemophobia, belonephobia, or difficult venous access.\n11. Blood donation or blood loss of ≥400 mL within 3 months prior to screening.\n12. History of drug dependence\u002Fabuse or illicit drug use, or a positive drug screening result.\n13. Smoking ≥5 cigarettes per day within 3 months prior to screening, or inability to commit to abstaining from tobacco products during the study, or a positive nicotine screening result.\n14. History of heavy alcohol consumption (\\>14 units per week; 1 unit ≈ 10 mL alcohol, equivalent to approx. 285 mL beer \\[3.5%\\], 25 mL spirits \\[40%\\], or 100 mL wine \\[10%\\]), inability to abstain from alcohol after screening, or a positive alcohol breath test.\n15. Daily consumption of excessive tea, coffee, or caffeine-containing beverages (more than 8 cups per day; 1 cup = 250 mL) within 14 days prior to screening.\n16. Ingestion of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos) or fruit products within 3 days prior to dosing.\n17. Special dietary requirements, or inability to comply with a standardized diet (e.g., standard meals) and dietary restrictions.\n18. Pregnancy or lactation, positive pregnancy test in females, unprotected sexual intercourse with a partner within 14 days prior to screening, use of oral contraceptives within 30 days prior to screening, or use of long-acting injectable or implanted estrogens\u002Fprogestogens within 6 months prior to screening.\n19. Requirement to drive long distances, work at heights, or operate complex machinery during the study.\n20. Other conditions that, in the investigator's opinion, would make the subject unsuitable for participation in this study.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},112,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a single-center, non-randomized, open-label, self-controlled, Phase I clinical trial to evaluate the drug-drug interactions (DDI) of JMKX003142 tablets in healthy adult participants.\n\nThe study consists of five cohorts (Cohorts 1, 2, 3, 4, and 5). A total of 24 participants are planned enrollment in each of Cohorts 1, 2, 3, and 5, while 16 participants are planned for Cohort 4.",[28],"ADPKD (Autosomal Dominant Polycystic Kidney Disease)","NOT_YET_RECRUITING","2026-04-27",{"date":32,"type":33},"2026-05-04","ACTUAL",{"date":35,"type":22},"2026-05-11",{"date":37,"type":22},"2027-02-28",{"name":39,"class":40},"Jemincare","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100632451","phase-1-trial-of-jyb1904-injection-in-adolescent-participants-100632451","NCT07513857","Trial of JYB1904 Injection in Adolescent Participants","A Multicenter, Single-arm, Phase Ib Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants Aged 12-17 Years","Inclusion Criteria:\n\n* Adolescent study participants (both male and female) who are at least 12 years of age but under 18 years of age at the time of signing the Informed Consent Form (ICF).\n* History of allergic diseases, including but not limited to food allergies, allergic rhinitis, allergic asthma, and chronic spontaneous urticaria.\n* Body weight ≥ 30 kg at screening.\n* Agreement to use effective contraception during the study and for 1 year following administration of the study drug.\n* The trial participant and their parent or legal guardian are able to understand and voluntarily sign the Informed Consent Form, and are able to comply with study visits and related procedures.\n\nExclusion Criteria:\n\n* Patients with a history of hypersensitivity to JYB1904 Injection, its excipients, or any anti-IgE therapy.\n* Any severe or poorly controlled chronic disease (including but not limited to severe arrhythmia, ischemic heart disease, NYHA Class III\u002FIV left ventricular failure, severe pulmonary disease, poorly controlled asthma, poorly controlled hypertension, poorly controlled diabetes, or poorly controlled hypothyroidism or hyperthyroidism) that, in the investigator's judgment, may compromise the safety of the trial participant.\n* History of severe allergic reactions, such as anaphylactic shock.\n* History of blood phobia, needle phobia, or difficulty with venipuncture; or abnormal skin at the administration site that may interfere with drug administration or the investigator's assessment (e.g., skin lesions, rashes, tattoos, etc.).\n* Total blood loss or blood donation of ≥400 mL within 12 weeks prior to screening, or receipt of a blood transfusion within 12 weeks prior to screening.","12 Years","17 Years",{"count":51,"type":22},12,[25],"This Phase Ib Trial is Meant to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Profiles of JYB1904 Injection in Adolescent Participants With Allergic Diseases.",[55],"Allergic Diseases",[55],"2026-04-01",{"date":59,"type":33},"2026-04-07",{"date":61,"type":22},"2026-05-17",{"date":63,"type":22},"2027-07-30",{"name":39,"class":40},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100629094","phase-1-a-study-to-investigate-the-effects-of-jmkx003142-on-qtc-interval-in-healthy-adults-100629094","NCT07470177","A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults","A Single-center, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Effect of a Single-dose of JMKX003142 on QTc Intervals in Healthy Participants","Inclusion Criteria:\n\n1. Participants must be able to return to the study center for follow-up visits as required by the protocol and be willing to comply with study policies, procedures, and constraints. They must be able to communicate effectively with the investigator, complete study-related materials, and understand the contents of the Informed Consent Form (ICF). A written ICF must be signed before any study-specific procedures are performed.\n2. Healthy Chinese males or females based on medical history and physical examination. At the time of signing the informed consent form (ICF), participants must be aged 18 to 45 years (inclusive), with a body weight ≥ 50 kg and a body mass index (BMI) between 19.0 and 28.0 $kg\u002Fm\\^2 (inclusive).\n3. Participants' health status will be determined by the investigator based on medical history, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG). All test results must be confirmed by the investigator as either normal or abnormal without clinical significance (NCS).\n4. Participants of childbearing potential must have no plans to conceive, freeze, or donate sperm\u002Feggs from the time of signing the informed consent form (ICF) until 3 months after the last dose, and must agree to use highly effective contraception methods.\n\nExclusion Criteria:\n\n1. History or presence of clinically significant diseases, including but not limited to: cardiovascular, respiratory, gastrointestinal, hematological, genitourinary, endocrine and metabolic, neurological, psychiatric, musculoskeletal, dermatological, lymphatic, or immunological systems, or diseases of the sense organs, as well as current systemic or local acute\u002Fchronic infections.\n2. Participants with any condition that increases the risk of bleeding, such as acute gastritis or active ulcers with bleeding, clinically significant thrombocytopenia or anemia, active pathological bleeding, or a history of intracranial hemorrhage.\n3. Vital signs at screening that meet any of the following criteria: systolic blood pressure (SBP) ≥ 140 mmHg or \\\u003C 90 mmHg; diastolic blood pressure (DBP) ≥ 90 mmHg or \\\u003C 50 mmHg; pulse rate \\> 100 bpm or \\\u003C 50 bpm; or axillary temperature \\> 37.2°C.\n4. History of QTc interval prolongation, or any clinically significant abnormal ECG findings at screening as determined by the investigator, or QTcF ≥ 450 ms, or QRS duration \\> 120 ms, or PR interval ≥ 200 ms.\n5. Clinical laboratory test results at screening showing serum potassium, magnesium, or calcium levels outside the normal range and judged by the investigator to be clinically significant.",{"count":73,"type":22},24,[25],"The primary objective of this study is to assess the effect of a therapeutic and supratherapeutic oral dose of JMKX003142 on the corrected cardiac QT interval relative to a placebo in healthy participants",[28],"2026-03-10",{"date":79,"type":33},"2026-03-13",{"date":81,"type":22},"2026-03-27",{"date":83,"type":22},"2026-06-23",{"name":39,"class":40},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":92,"minAge":18,"maxAge":19,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100628547","phase-1-mass-balance-and-absolute-bioavailability-study-of-jmkx003142-in-healthy-volunteers-100628547","NCT07463053","Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy Volunteers","A Study to Evaluate the Mass Balance and Absolute Bioavailability of [14C]JMKX003142 in Healthy Male Participants","Inclusion Criteria:\n\n1. Chinese healthy males.\n2. The age between 18 and 45 years (extremes included), on the date of signing the informed consent form (ICF).\n3. Body mass index (BMI) range of 19-26.0 kg\u002Fm² (inclusive of boundary values), with body weight not less than 55.0 kg.\n\nExclusion Criteria:\n\n1. Abnormal findings with clinical significance on comprehensive physical examination, vital signs, digital rectal examination, laboratory tests (complete blood count, blood biochemistry, coagulation function, urinalysis, fecal routine with occult blood, thyroid function), ophthalmological examination, 12-lead electrocardiogram, chest X-ray (posteroanterior view), and abdominal ultrasound (liver, gallbladder, pancreas, spleen, kidneys).\n2. White blood cell count and\u002For hemoglobin below the lower limit of the normal range in complete blood count.\n3. Resting corrected QT interval (QTcF) \\>450 ms (corrected by Fridericia's formula, QTcF = QT\u002FRR\\^1\u002F3).\n4. Hepatitis B surface antigen or E antigen positive, anti-HCV IgG positive, syphilis treponemal antibody positive, and HIV antigen\u002Fantibody combination test positive.\n5. Subjects with gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome, or those with a history of severe vomiting or diarrhea within one week prior to screening.","MALE",{"count":94,"type":22},8,[25],"A phase 1 healthy volunteer study to assess the excretion and metabolism as well as the absolute bioavailability of oral JMKX003142. The study will be conducted in two parts: Part 1 to assess the mass balance of JMKX003142 using orally administered radiolabelled JMKX003142; part 2 will assess the absolute bioavailability using JMKX003142 and radiolabelled JMKX003142 as intravenous and oral forms",[28],"2026-03-06",{"date":77,"type":33},{"date":101,"type":22},"2026-03-18",{"date":103,"type":22},"2026-06-11",{"name":39,"class":40},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100628270","phase-2-trial-of-jyb1904-injection-in-patients-with-perennial-allergic-rhinitis-100628270","NCT07459452","Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection Combined With Background Therapy in Patients With Perennial Allergic Rhinitis","Inclusion Criteria:\n\n1. Adult participants ≥18 years and ≤65 years of age at the time of signing the informed consent form (ICF).\n2. Physician-diagnosed PAR at screening, symptoms of allergic rhinitis present for a minimum of 2 years.\n3. Participants must have been on stable treatment with intranasal corticosteroids (INCS), with or without other background medications for at least four consecutive weeks before randomization, and rTNSS≥6 at screening.\n4. Within 1 year prior to screening or at screening, participants must have positive indoor allergen SPT and\u002For positive antigen-specific serum IgE to indoor allergens . Participants must have clinical symptoms associated with perennial allergen positivity (assessed by SPT) or positive serum antigen-specific IgE at study entry .\n5. A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.\n6. Participants who have concomitant asthma must use permitted regular asthma treatment during the study and have been stable in the 3 months prior to screening.\n7. Is willing and able to comply with daily eDiary.\n8. Participants must complete the eDiary during the baseline evaluation period (2 weeks prior to randomization) and meet the following criteria: (1) complete the eDiary for at least 4 days per week; and (2) rTNSS score ≥6 at randomization (average of Day-7 to Day-1).\n\nExclusion Criteria:\n\n1. Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy.\n2. Have received treatment with any rescue medication or adjustment to background therapy medications during the baseline evaluation period.\n3. Prior intolerance or inadequate response to omalizumab.\n4. Contraindications or hypersensitivity to antihistamines or intranasal corticosteroids, or history of anaphylaxis.\n5. Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 2-week baseline evaluation period and the 24-week double-blind induction period.\n6. Anticipates significant changes in their daily environmental exposure during the 2-week baseline evaluation period and the 24-week double-blind induction period.\n7. Has a history of nasal polyps or nasal polyps present at screening, moderate-to-severe nasal septum deviation, or rhinitis secondary to other causes.\n8. Has a known history of recurrent acute or chronic sinusitis.","65 Years",{"count":114,"type":22},135,[116],"PHASE2","This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.",[119],"Perennial Allergic Rhinitis",[121],"PAR","2026-03-05",{"date":124,"type":33},"2026-03-09",{"date":126,"type":22},"2026-04",{"date":128,"type":22},"2028-10",{"name":39,"class":40},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100623867","phase-3-trial-of-jyb1904-injection-in-adult-patients-with-chronic-spontaneous-urticaria-100623867","NCT07402213","Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines","Inclusion Criteria:\n\n* Male or female participant must be ≥18 years old at the time of signing the informed consent.\n* Participants are diagnosed with CSU for ≥6 months before screening.\n* Participants suffer from itching and hives for at least 6 consecutive weeks at any time before screening.\n* UAS7 (range 0\\~42) ≥16, ISS7 (range 0\\~21) ≥8 during 7 days before randomization.\n* Participants treated with stable dose of second-generation H1 antihistamines (up to 4x approved dose) for at least 6 consecutive weeks before randomization, switching medications, or changing drug dosage or frequency is not allowed within 3 weeks before randomization.\n* Participants have ≥6 days record of UAS7 before randomization.\n\nExclusion Criteria:\n\n* Participants who suffer from inducible urticaria with definite inducements, including urticaria factitia (dermatographism), cold contact, heat contact, solar, pressure, delayed pressure, aquagenic, cholinergic or contact urticaria, etc.\n* Participants who suffer from any other skin diseases with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, etc.\n* Participants who suffer from other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria or acquired\u002Fdrug-induced urticaria.\n* Participants who are contraindicated or hypersensitive to antihistamines or any of its component (such as fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, rupatadine, bilastine).\n* History of anaphylactic shock.",{"count":138,"type":22},180,[140],"PHASE3","This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.",[143],"Chronic Spontaneous Urticaria",[145],"CSU","2026-02-03",{"date":148,"type":33},"2026-02-11",{"date":150,"type":22},"2026-03-31",{"date":152,"type":22},"2028-04-28",{"name":39,"class":40},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":177},"100608944","phase-1-a-study-of-jmkx005425-in-patients-with-msi-hdmmr-advanced-solid-tumors-100608944","NCT07208136","A Study of JMKX005425 in Patients With MSI-H\u002FdMMR Advanced Solid Tumors","An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX005425 Tablets in Subjects With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors","Inclusion Criteria:\n\n1. Have a microsatellite instability-high (MSI) and\u002For mismatch repair deficiency (dMMR), histologically or cytologically documented advanced solid tumor.\n2. Has at least one measurable lesion per RECIST v1.1.\n3. Has a life expectancy of ≥ 12 weeks.\n4. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicities from prior anti-tumor therapy has not recovered to Grade 1 or below per CTCAE v5.0.\n2. History of prior malignancy in the past 3 years, with the exception of curatively treated malignancies.\n3. Has the dysphagia, or impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study drug.\n4. Has the severe chronic or active infection\n5. Has a history of severe cardiovascular disease.\n6. Subject is pregnant or breastfeeding.","80 Years",{"count":163,"type":22},102,[25],"This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and\u002For mismatch repair deficiency (dMMR) advanced solid tumors.",[167],"Advanced Solid Tumors","RECRUITING","2025-11-27",{"date":171,"type":33},"2025-12-01",{"date":173,"type":33},"2025-10-22",{"date":175,"type":22},"2028-12",{"name":39,"class":40},1,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":177},"100611568","phase-3-phase-3-trial-of-jmkx001899-versus-docetaxel-in-previously-treated-advanced-or-metastatic-kras-g12c-mutant-nsclc-100611568","NCT07242274","Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","A Multicenter, Randomized, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of JMKX001899 Versus Docetaxel in Previously Treated Patients With KRAS G12C-Mutant Advanced or Metastatic Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically or cytologically confirmed NSCLC.\n3. Failure of at least one prior line of therapy for locally advanced\u002Fmetastatic disease, that included a platinum-based chemotherapy and a PD-1\u002FPD-L1 inhibitor.\n4. At least one measurable lesion as defined by RECIST version 1.1.\n\nExclusion Criteria:\n\n1. Known concomitant presence of other oncogenic driver mutations or rearrangements with established targeted therapies .\n2. Previous treatment with any KRAS G12C-targeted agent.\n3. Prior docetaxel therapy in the locally advanced\u002Fmetastatic setting.",{"count":186,"type":22},472,[140],"This is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic non-small cell lung cancer (NSCLC).\n\nKRAS G12C mutation is present in a subset of NSCLC patients. While docetaxel is a standard chemotherapy option, JMKX001899 is an investigational, targeted therapy designed to selectively inhibit the KRAS G12C mutation. This trial aims to determine whether JMKX001899 offers a superior clinical benefit compared to standard chemotherapy.",[190],"NSCLC (Non-small Cell Lung Cancer)","2025-11-17",{"date":193,"type":33},"2025-11-21",{"date":195,"type":22},"2025-12-31",{"date":197,"type":22},"2029-12-30",{"name":39,"class":40},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100606877","phase-1-drug-drug-interaction-of-jmkx003142-with-amiodarone-and-febuxostat-in-healthy-subjects-100606877","NCT07181265","Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects","A Single-center, Non-randomized, Open-label, Self-controlled Phase I Drug-drug Interaction Clinical Study to Evaluate the Pharmacokinetics of JMKX003142 With Amiodarone, and Febuxostat in Chinese Healthy Subjects","Inclusion Criteria:\n\n1. Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.\n2. Healthy adult males and\u002For females, 18 to 45 years of age (inclusive) at the date of signed consent form. Body mass index (BMI) greater than or equal to 18 and less than 32 (kg\u002Fm2) and a minimum body weight of 45 kg.\n3. The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.\n4. Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm\u002Fegg for the time period specified above.\n\nExclusion Criteria:\n\n1. Subjects having hypersensitivity to study drug or have a history of allergies to multiple drugs, foods, or other substances\n2. History or presence of significant circulatory system, respiratory system, digestive system, blood system, urinary and reproductive system, endocrine and metabolic system, nervous system, mental system, muscular and skeletal system, skin system, lymphatic system, immune system, Otolaryngology or other related systems disease or disorder. as well as systemic or local acute or chronic infections.\n3. Subjects with dysphagia, gastrointestinal diseases, or any conditions that may affect drug absorption; such as a history of hepatobiliary and pancreatic diseases, gastrointestinal diseases, gastrointestinal surgery (except appendectomy), or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.\n4. Vital signs during the screening period meet any of the following conditions: systolic blood pressure \\>140 mmHg or \\\u003C90 mmHg; diastolic blood pressure \\>90 mmHg or \\\u003C50 mmHg (Cohort 1: diastolic blood pressure \\>90 mmHg or \\\u003C60 mmHg); pulse \\>100 beats\u002Fmin or \\\u003C50 beats\u002Fmin (Cohort 1: pulse \\>100 beats\u002Fmin or \\\u003C60 beats\u002Fmin); ear temperature \\>37.5°C or \\\u003C35°C.\n5. History of QTc interval prolongation or abnormal ECG results during screening, QTcF ≥ 450 ms for males or ≥ 470 ms for females, or QRS interval \\> 120 ms.",{"count":207,"type":22},48,[25],"This is a open-label, non-randomized, multiple oral dosings, three-period, drug-drug interaction study of JMKX003142 tablet, Amiodarone Hydrochloride Tablets and Febuxostat Tablets in Chinese healthy adult subjects",[211],"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","2025-09-12",{"date":214,"type":33},"2025-09-18",{"date":216,"type":22},"2025-10-30",{"date":218,"type":22},"2026-06-30",{"name":39,"class":40},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},"100567618","phase-2-a-dose-finding-study-of-jmkx003142-in-treatment-of-renal-edema-100567618","NCT06670534","A Dose-finding Study of JMKX003142 in Treatment of Renal Edema","A Multicenter,Randomized,Open-label,Positive-controlled Study to Evaluate the Efficacy and Safety of JMKX003142 in Renal Edema Patients","Inclusion Criteria:\n\n* Patients who can fully understand the purpose and process of the study and voluntarily sign the informed consent form（ICF）;\n* Age ≥ 18 years old during screening;\n* Diagnosed as renal edema during screening;\n* Estimated glomerular filtration rate（eGFR） ≥ 15 mL\u002Fmin\u002F1.73m2 during screening.\n\nExclusion Criteria:\n\n* Patients who are receiving the renal replacement therapy during screening or patients who require renal replacement therapy in the short term evaluated by the researchers;\n* Patients who are suspected with hypovolemia;\n* Patients with the following diseases or symptoms: acute thrombosis, diarrhea, and difficulty urinating;\n* Patients who are unable to sense thirst or who have difficulty with fluid intake;\n* Patients who have received arginine vasopressin-V2R blockers within 30 days prior to the screening examination;\n* The following laboratory indicators are abnormal: glutamic pyruvic transaminase ≥ 1.5 ×upper limit of normal, glutamic oxaloacetic transaminase ≥ 1.5 × upper limit of normal, serum sodium\\> upper limit of normal, D-dimer ≥ 2 × upper limit of normal;\n* Patients who received diuretics or treatments with diuretic effects from Day-2 to randomization;\n* During screening, systolic blood pressure \\\u003C90mmHg\u002Fdiastolic blood pressure\\\u003C60mmHg, systolic blood pressure\\>160mmHg\u002Fdiastolic blood pressure \\>100mmHg;\n* Patients who have a history of allergies to ≥ 3 substances, or are currently in an allergic state;\n* Female patients who are breast-feeding or who have a positive pregnancy test result prior to receiving investigational product (IMP);\n* Sexually active males or women of childbearing potential (WOCBP) who do not agree to practice birth control or remain abstinent during the trial and for 30 days after the final IMP administration.",{"count":228,"type":22},216,[116],"To Evaluate the Safety, Efficacy, and Pharmacokinetic Characteristics of JMKX003142 Administered Randomly, Open-label, Active-controlled Study in Chinese Renal Edema Patients.",[232,233],"Edema Secondary","Edema Leg",[235,236],"renal edema","edema due to kidney diseases","2025-08-07",{"date":239,"type":33},"2025-08-12",{"date":241,"type":33},"2025-01-07",{"date":243,"type":22},"2026-07-30",{"name":39,"class":40},2,{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":177},"100577619","phase-2-trial-of-jmkx003142-in-participants-with-rapidly-progressive-autosomal-dominant-polycystic-kidney-disease-adpkd-100577619","NCT06800651","Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Inclusion Criteria:\n\n* Able to understand the procedures of this trial and provide written informed consent voluntarily;\n* Age between 18 to 55 years, male or female;\n* ADPKD diagnostic criteria were met before randomization;\n* Rapidly progressive ADPKD criteria were met.\n\nExclusion Criteria:\n\n* 12 weeks prior to screening, patients had taken tolvaptan or another ADPKD improvers, or patients who were assessed by the investigator to be likely to use diuretic during the trial period;\n* Praticipants who are unable to feel thirst, or have difficulty with fluid\u002Ffood intake;\n* Patients who have previously received decompression surgery for renal cysts; or who received major surgery within 12 weeks before signing the ICF;\n* The investigator think that the praticipant is unable to comply with the requirements of the trial or cannot be evaluated by the trial.","55 Years",{"count":114,"type":22},[116],"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)",[28],"2025-06-30",{"date":260,"type":33},"2025-07-03",{"date":262,"type":33},"2025-03-13",{"date":264,"type":22},"2027-05-30",{"name":39,"class":40},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":177},"100588862","phase-1-a-phase-ib-study-of-jmkx001899-in-combination-with-other-therapies-in-advanced-nsclc-harboring-kras-g12c-mutation-100588862","NCT06946927","A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation","A Phase Ib, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of JMKX001899 in Combination With Other Therapies in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation.","Inclusion Criteria:\n\n1. Histologically or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV NSCLC disease.\n2. Known KRAS G12C mutation, and negative results for other driver genes with approved targeted therapies.\n3. Measurable disease according to RECIST 1.1.\n4. An Eastern Cooperative Group (ECOG) performance status of 0 or 1.\n5. Adequate organ function.\n\nExclusion Criteria:\n\n1. Subjects with carcinomatous meningitis or spinal cord compression; or with other evidence indicating that central nervous system (CNS) metastases or leptomeningeal metastases are not yet controlled.\n2. Prior chemotherapy, radiotherapy, immunotherapy or treatment with an investigational agent within 4 weeks of receipt of study drug (within 6 weeks for nitrosoureas, mitomycin C; within 2 weeks of small molecule targeted therapies, traditional medicine with anticancer indication).\n3. History of prior malignancy in the past 3 years, with the exception of curatively treated malignancies.\n4. Gastrointestinal (GI) tract disease causing the inability to take oral medication or affect drug absorption.","75 Years",{"count":275,"type":22},72,[25],"This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.",[279],"NSCLC (Advanced Non-small Cell Lung Cancer)","2025-06-26",{"date":282,"type":33},"2025-07-01",{"date":284,"type":33},"2025-06-06",{"date":286,"type":22},"2027-12",{"name":39,"class":40},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100589023","phase-2-a-dose-finding-study-of-jmkx003142-in-treatment-of-cardiac-edema-100589023","NCT06949020","A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema","Efficacy and Safety of JMKX003142 Injection in Heart Failure Patients With Volume Overload：A Phase II, Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n1. Can fully understand the purpose and process of the study and voluntarily sign the informed consent form;\n2. Age ≥ 18 years old when signing the informed consent form;\n3. At the screening stage, it has been definitely diagnosed as heart failure, and it is combined with one of the following clinical manifestations related to body fluid retention: edema of both lower limbs, jugular vein engorgement, pulmonary congestion;\n4. The screening phase is currently undergoing or preparing to use one of the following diuretic therapy as background treatment during the run-in period:\n\n1\\) At least 40mg\u002Fday of furosemide equivalent loop diuretics; 2) Any dose of loop diuretics combined with thiazide diuretics; 3) Any dose of loop diuretics combined with aldosterone receptor antagonists or other potassium sparing diuretics.\n\n5\\. After the background treatment in the run-in period, the subject still has the following two conditions:\n\n1. One of the following clinical manifestations related to fluid retention still exists after the induction phase treatment: edema of both lower limbs, jugular vein dilatation, pulmonary congestion;\n2. During the import phase, the weight of D-1 does not change by more than 1.0 kg compared to D-3.\n\nExclusion Criteria:\n\n1. Edema caused by diseases other than heart failure；\n2. Subjects with ventricular assist devices during screening;\n3. Subjects diagnosed with active myocarditis, myocardial amyloidosis, hypertrophic cardiomyopathy (excluding dilated phase), or valve disease with obvious valve stenosis during screening;\n4. Acute myocardial infarction occurred within 30 days prior to screening; subjects with a history of persistent ventricular tachycardia or ventricular fibrillation within the 30 days prior to screening (those without implantable defibrillators); History of cerebrovascular disease within 6 months prior to screening (excluding asymptomatic cerebral infarction);\n5. Subjects with hypovolemia or suspected hypovolemia;\n6. Subject cannot feel thirst or have difficulty in fluid intake during screening;\n7. During screening, the systolic blood pressure is less than 90mmHg or the diastolic blood pressure is less than 60mmHg;\n8. Administered with tolvaptan 14days before randomization ；\n9. Pregnancy (female pregnancy test positive) or lactation period;",{"count":296,"type":22},160,[116],"To Evaluate the Safety, Efficacy, and Pharmacokinetic\u002FPharmacodynamics Characteristics of JMKX003142 injection Administered Randomly,Double-blind, Placebo-controlled Study in Chinese Cardiacl Edema Patients.",[300],"Cardiac Edema",[302,303],"fluid retention","heart failure","2025-04-22",{"date":306,"type":33},"2025-04-29",{"date":308,"type":22},"2025-06-01",{"date":310,"type":22},"2027-05-31",{"name":39,"class":40},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":273,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":177},"100572957","phase-1-a-phase-ib-study-of-jmkx000197-injection-in-the-treatment-of-malignant-pleural-effusion-100572957","NCT06740019","A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion","A Phase Ib, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion","Inclusion Criteria:\n\n1. The participant voluntarily joined the study, signed an informed consent form, and had good compliance.\n2. Age ≥ 18 years and ≤ 75 years old, regardless of gender.\n3. Participants with advanced solid tumors diagnosed by histopathology or cytopathology.\n4. Malignant pleural effusion confirmed by histopathology or cytopathology or clinically diagnosed as moderate or above and requiring drainage.\n5. Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 2.\n6. Life expectancy of at least 3 months.\n7. Adequate organ function.\n8. Female participants of childbearing potential should agree to use contraception to prevent pregnancy until 6 months after discontinuation of JMKX000197. The serum pregnancy test result should be negative 7 days before enrollment and must be a non-lactating participant. Male participants must agree to use effective contraception during the study and for 6 months after discontinuation of JMKX000197.\n\nExclusion Criteria:\n\n1. Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.\n2. Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.\n3. Have used interferon gene stimulating factor (STING) agonists for pleural perfusion。\n4. Known allergies to the study drug or its excipient components.\n5. Have participated in other clinical trials within 28 days prior to randomization.\n6. Major surgery within 28 days prior to randomization.\n7. Central nervous system metastatic disease, leptomeningeal disease, or cord compression.\n8. Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.\n9. Uncontrollable systemic infections (viruses, bacteria, fungi), including but not limited to positive HBsAg and HBV DNA, positive HCV RNA, positive HIV antibody test or combined infections within the first 28 days of randomization and require systemic anti-infective treatment.\n10. Have a history of organ transplantation.\n11. Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.",{"count":320,"type":22},30,[25],"A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion",[324],"Malignant Pleural Effusions (Mpe)","2025-04-01",{"date":327,"type":33},"2025-04-04",{"date":329,"type":33},"2024-12-28",{"date":331,"type":22},"2026-11",{"name":39,"class":40},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":4},"100580081","phase-1-study-of-jmkx003948-ophthalmic-suspension-in-healthy-participants-100580081","NCT06832657","Study of JMKX003948 Ophthalmic Suspension in Healthy Participants","A Randomized, Double-blind, Placebo-controlled Phase 1 Study of JMKX003948 Ophthalmic Suspension to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Dose(s) in Healthy Participants","Inclusion Criteria:\n\n1. Healthy adult males and\u002For females, 18 to 45 years of age (inclusive) at the date of signed consent form.\n2. Body mass index (BMI) greater than or equal to 18 and less than 32 (kg\u002Fm2) and a minimum body weight of 45 kg.\n3. Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study.\n4. Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm\u002Fegg for the time period specified above.\n\nExclusion Criteria:\n\n1. History of disease of ocular surface, fundus, central nervous system, psychiatric and psychological condition, cardiovascular system, kidney, liver, digestive system, respiratory system, or metabolic\u002Fendocrine system, or other disease that in the opinion of the Investigator (or medically qualified designee) may make participation unsafe for the participant or interfere with study evaluations.\n2. Any abnormal examination with clinical significance may interfere with study evaluations in opinion of the Investigator (or medically qualified designee).\n3. History of eye trauma or surgery including LASIK\u002FLASEK.\n4. Any corrected visual acuity \\\u003C 20\u002F20, or intraocular pressure ≥ 21 mmHg.\n5. Clinically significant abnormalities on ophthalmic examination that would hinder the assessment of the eye or data collection at the discretion of the Investigator and\u002For ophthalmologist (or medically qualified designee).",{"count":341,"type":22},40,[25],"The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.\n\nParticipant will be randomized to receive either JMKX003948 Ophthalmic Suspension (1%, 2%, 3% or 5%) or matching placebo (JMKX003948 Ophthalmic Suspension: placebo= 6: 2, N=8 per cohort).\n\nFive cohorts (Cohort 1-5) are planned. Cohorts could also de-escalate to a lower concentration if current formulation was not tolerated (Cohort 1b, 2b and 3b). In case of de-escalation, Cohort 1b and 2b will continue to escalate to Cohort 1c and Cohort 2c, respectively.\n\nParticipants will be admitted to the site on Day -1 after screening (up to 28 days), and remain domiciled until Day 14 for Cohort 1-4, Day 8 for other cohorts.",[345,346],"Age-Related Macular Degeneration (AMD)","Diabetic Macular Edema (DME)","2025-02-12",{"date":349,"type":33},"2025-02-18",{"date":351,"type":22},"2025-02",{"date":353,"type":22},"2025-12",{"name":39,"class":40},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":360,"conditions":365,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":245},"100567126","phase-2-evaluate-the-efficacy-and-safety-of-jmkx003002-in-end-stage-renal-disease-patients-on-hemodialysis-with-hyperphosphatemia-100567126","NCT06664125","Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia","Inclusion Criteria:\n\n1. Able to understand the procedures of this trial and provide written informed consent voluntarily;\n2. Age ≥ 18 years, male or female;\n3. On a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit;\n4. Serum phosphorus within the trial-required range.\n\nExclusion Criteria:\n\n1. Any history of inflammatory bowel disease or diarrheal irritable bowel syndrome;\n2. Pregnant or breastfeeding;\n3. Any history of a parathyroid intervention;\n4. Diarrhea or loose stools occurred within 1 week prior to randomization.",{"count":363,"type":22},50,[116],[366],"Hyperphosphatemia","2025-01-31",{"date":369,"type":33},"2025-02-03",{"date":371,"type":33},"2024-12-30",{"date":373,"type":22},"2025-09-30",{"name":39,"class":40},{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":177},"100555226","phase-2-trial-of-jyb1904-in-chronic-spontaneous-urticaria-100555226","NCT06509334","Trial of JYB1904 in Chronic Spontaneous Urticaria.","A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Adult Patients with Chronic Spontaneous Urticaria Inadequately Controlled by H1 Antihistamines","Inclusion Criteria:\n\n* Male or female adult subjects (≥18 years of age).\n* Diagnosis of Chronic Spontaneous Urticaria(CSU) ≥ 3 months prior to Screening Visit 1 and previously inadequately controlled with a second-generation H1 antihistamine.\n* Itching and hives lasting ≥ 6 weeks prior to Screening Visit 1.\n* Have a UAS7 (range 0 - 42) ≥ 16, an ISS7 (range 0 - 21) ≥ 6, and an HSS7 (range 0 - 21) ≥ 6 within 7 days prior to randomization.\n\nExclusion Criteria:\n\n* Induced urticaria with a defined trigger, including artificial urticaria (cutaneous scratches), cold-contact, heat-contact, solar, pressure, delayed-pressure, water-source, cholinergic, or contact urticaria\n* Any other dermatological condition with chronic itching, such as atopic dermatitis, herpetic pemphigoid, herpetic dermatitis, senile itching, or psoriasis, which in the opinion of the investigator may affect the study assessment and study results\n* Other conditions with symptoms of urticaria or angioedema, including but not limited to urticarial vasculitis, pigmented urticaria, erythema multiforme, mastocytosis, hereditary urticaria, or acquired\u002Fdrug-induced urticaria.\n* Previous allergic reaction or poor efficacy with omalizumab.\n* Contraindication or hypersensitivity to antihistamines (e.g., fexofenadine, loratadine, desloratadine, cetirizine, levocetirizine, rupatadine, bilastine) or any of the ingredients.",{"count":114,"type":22},[116],"This Phase II Trial is Meant to Evaluate the Efficacy, Safety and Tolerability of JYB1904 Injection in Patients With Chronic Spontaneous Urticaria.",[143],"2024-11-26",{"date":388,"type":33},"2024-11-29",{"date":390,"type":33},"2024-08-04",{"date":392,"type":22},"2026-07-15",{"name":39,"class":40},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":401,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":4},"100566729","phase-1-study-to-evaluate-the-drug-drug-interaction-of-jmkx003142-in-healthy-subjects-100566729","NCT06658964","Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects","A Single-center, Non-randomized, Open-label, Self-controlled Phase 1 Clinical Study to Evaluate Drug-drug Interactions of JMKX003142 Tablets in Healthy Subjects","Inclusion Criteria:\n\n* Fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the informed consent,\n* Healthy male and female subjects aged ≥18 years and ≤45 years old, Male weight ≥50kg, female weight ≥45kg, body mass index ≥19 kg\u002Fm2 and ≤28 kg\u002Fm2,\n* The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant.\n\nExclusion Criteria:\n\n* HBV surface antigen, HCV antibody, HIV, or syphilis are positive during screening,\n* At the time of screening, the vital signs are within the following ranges: systolic blood pressure \\\u003C90 mmHg or \\>140 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>90 mmHg, pulse \\\u003C50 bpm or \\>100 bpm and ear temperature 37.5℃or\\\u003C35℃,\n* More than 5 cigarettes per day during the 3 months prior to screening, Or were unable to quit smoking\u002Fcontaining tobacco products during the trial,\n* Have special requirements for diet and cannot comply with the diet provided and corresponding regulations.",{"count":207,"type":22},[25],"To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of JMKX003142 in healthy subjects.",[405],"ADPKD (autosomal Dominant Polycystic Kidney Disease)","2024-10-23",{"date":408,"type":33},"2024-10-26",{"date":410,"type":22},"2024-11-05",{"date":412,"type":22},"2025-03-21",{"name":39,"class":40},{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":177},"100558299","phase-1-trial-of-jmkx003801-in-healthy-participants-100558299","NCT06549309","Trial of JMKX003801 in Healthy Participants","A Phase I, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of JMKX003801 in Healthy Participants","Inclusion Criteria:\n\n* The subjects have a thorough understanding of the study content, process, and potential adverse effects, and are willing to complete the study according to the requirements of the experimental protocol;\n* Healthy adult males and\u002For females, 18 to 45 years of age;\n* Body mass index (BMI) ≥ 19 and ≤ 28.0 (kg\u002Fm2) ,weight ≥45kg (female) or ≥50kg (male) .\n\nExclusion Criteria:\n\n* Had or currently have serious clinical diseases related to circulatory system, respiratory system, digestive system, nervous system, endocrine system, blood lymphatic system, genitourinary system or psychiatry, or any other diseases judged by investigators that will be interference to the results of this study;\n* Use of any over-the-counter (OTC) medication, prescription medicine, Chinese herbal medicine , within 2 weeks prior to the time of informed consent signed;\n* Pregnant or lactating women;\n* Other conditions unsuitable for the trial judged by the investigators.",{"count":422,"type":22},70,[25],"To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003801 Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Dose in Chinese Healthy Adult Participants",[426],"Healthy",[428,429,430],"Safety","Tolerability","Pharmacokinetics","2024-09-24",{"date":433,"type":33},"2024-09-26",{"date":435,"type":33},"2024-08-17",{"date":437,"type":22},"2025-06-12",{"name":39,"class":40},{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":177},"100540777","phase-1-a-study-of-jmkx003948-tablets-in-patients-with-renal-cell-carcinoma-100540777","NCT06321250","A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma","An Open-label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX003948 Tablets in Patients With Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Has the ability to understand and willingness to sign a written informed consent form.\n2. Male or female from 18 years of age or older.\n3. Histologically confirmed locally advanced or metastasis clear cell renal cell carcinoma.\n4. Has at least one measurable lesion per RECIST v1.1.\n5. Has a life expectancy of ≥ 12 weeks.\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Patients with known active CNS metastases and\u002For cancerous meningitis.\n2. Has received any type of systemic anticancer monoclonal antibodies or other immunosuppressants within 4 weeks prior to the first dose. Has received prior chemotherapy, targeted therapy, or other investigational therapy within 2 weeks prior to the first dose.\n3. Has failed to recover from a ≥ grade 2 adverse event due to prior anti-tumor therapy.\n4. Has impaired heart function,or clinically significant cerebrovascular and cardiovascular disease.\n5. Subjects with dysphagia or known drug absorption disorders.\n6. Has a history of any other malignancy within 5 years.\n7. Has severe oncological complications.\n8. Is currently participating in other clinical studies.\n9. Subjects with be unsuitable for participation in the trial evaluated by investigator.",{"count":447,"type":22},80,[25],"This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.",[451],"Renal Cell Carcinoma Metastatic","2024-07-06",{"date":454,"type":33},"2024-07-09",{"date":456,"type":33},"2024-03-14",{"date":458,"type":22},"2027-04-30",{"name":39,"class":40},{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":4},"100552504","phase-1-to-assess-the-effects-of-single-dose-of-jmkx001899-on-qtc-interval-in-healthy-subjects-100552504","NCT06473948","To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects","A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect of JMKX001899 on the QTc Interval in Healthy Subjects","Inclusion Criteria:\n\n1. Healthy, adult, male or female 18-45 years of age, inclusive.\n2. Body mass index (BMI) between 19 and 28 kg\u002Fm2 (inclusive) and weight at least 50 kg.\n3. Participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n\nExclusion Criteria:\n\n1. Patients with a history of clinically significant diseases including, but not limited to, gastrointestinal, renal, liver, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, or cardiovascular and cerebrovascular diseases, epilepsy, bipolar disorder\u002Fmania, intraocular hypertension, or acute angle-closure glaucoma.\n2. Female subjects with a positive pregnancy test or lactating.\n3. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or Treponema pallidum（TP-Ab）",{"count":468,"type":22},27,[25],"Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers",[472],"Solid Tumor, Adult","2024-06-19",{"date":475,"type":33},"2024-06-25",{"date":477,"type":22},"2024-07-10",{"date":479,"type":22},"2025-02-27",{"name":39,"class":40},""]